Research study Program year 2019 Source: CMS Open Payments

An Open-Label Study to Assess Safety

ClinicalTrials.gov NCT03645499

Research payments

$529,190

27 payments

Through program year 2019, $529,190 in research payments was reported against An Open-Label Study to Assess Safety, across 27 payments, paid by Taro Pharmaceuticals USA, Inc..

Paid by: Taro Pharmaceuticals USA, Inc.
ClinicalTrials.gov: NCT03645499

By program year

1 row

Year	Kind	Amount	Payments
2019	Research	$529,190	27

Breakdown

Who paid Research payments · program year 2019

Taro Pharmaceuticals USA, Inc. $529,190 27 payments

Who received the money Research payments · program year 2019

Fxm Clinical Research Miami Llc Organisation paid for research $279,055 10 payments
Fxm Clinical Research Miramar LLC Organisation paid for research $235,800 12 payments
3A Research, LLC Organisation paid for research $9,115 2 payments
FXM Research Corp Organisation paid for research $5,220 3 payments

Usually the institution or organisation running the study, not a person.

What the money was spent on Research payments · program year 2019

Professional salary support $513,940 19 payments
Overhead $9,000 3 payments
Other $6,250 5 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

Records

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

Principal investigators named

3 shown

Named on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.

What you are looking at

Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.